The road to antibiotic innovation blocked by economic barriers.

Cracking the Code: How to Solve the Antibiotic R&D Crisis

Samir D’Costa monogram
Samir D’Costa in Health & Wellness October 2026 • 4 min read.

"Discover why major pharmaceutical companies are abandoning antibiotic research and what innovative solutions can revitalize the development of life-saving drugs."


For decades, the discovery and development of new antibiotics was a booming field, driven by scientific breakthroughs and lucrative patents. Pharmaceutical giants led the charge, consistently introducing new drugs to combat emerging resistance. However, the landscape has dramatically shifted since the 1990s. Companies have redirected their focus to more profitable ventures, leading to a significant decline in the number of new antibiotics reaching the market.

This decline coincides with a surge in antibiotic overuse and poor regulation, exacerbating the spread of drug resistance. Global antibiotic consumption soared by 65% between 2000 and 2015, particularly in low- and middle-income countries. As a result, potential and existing developers now face substantial economic barriers, making the R&D of novel antibiotics a risky and often unrewarding endeavor.

In this article, we delve into the economic factors that have disrupted the antibiotics market and examine ongoing efforts to address these challenges. While progress has been made in stimulating R&D, the drug pipeline remains insufficient to meet the growing clinical need. We propose actionable recommendations to tackle the most pressing economic issues hindering the development of new antibiotics.

AI Search Multiple angles on this topic

Recent U.S. Hospital-Onset Trends

In July 2024, the CDC reported that six bacterial antimicrobial-resistant hospital-onset infections increased by a combined 20% during the COVID-19 pandemic compared with the pre-pandemic period. They peaked in 2021 and remained above pre-pandemic levels, according to the CDC’s 2021–2022 threat report. WHO’s AMR data portal tracks human-health indicators to monitor national and global responses to antimicrobial resistance. (Reference URL 1; Reference URL 2)

Why is Antibiotic R&D Facing a Crisis?

The road to antibiotic innovation blocked by economic barriers.

Reinvigorating antibiotic R&D is a complex task due to a mix of economic, regulatory, and scientific hurdles. Economic issues, in particular, create significant distress for developers throughout the entire value chain. These issues are compounded by regulatory complexities and scientific challenges, creating a perfect storm that discourages investment and innovation.

One of the primary obstacles is the scientific difficulty in identifying new antibacterial molecules and mechanisms of action. Traditional methods of studying natural antimicrobial activities have become less effective over time. This has led to a decline in the number of experts in antibiotic discovery as research centers close and pharmaceutical companies divest from the field.

  • Difficulty in Basic Science: Identifying new antibacterial molecules and mechanisms of action is challenging.
  • Shrinking Talent Pool: The closure of research centers and divestiture by pharmaceutical companies have led to a shortage of experts.
  • Preclinical Phase Challenges: Many drug candidates fail to progress from basic science to clinical trials due to funding gaps and the lack of suitable models for drug-resistant bacterial infections.
AI Search Multiple angles on this topic

Research and the Antibiotic Pipeline

WHO reports that antibacterial development remains focused on Gram-negative pathogens, some of which are resistant to last-resort antibiotics. These bacteria can develop new ways to resist treatment and pass genetic material that can make other bacteria drug resistant. A 2024 Nature article argues that addressing antimicrobial resistance requires a sustainable antibiotic R&D ecosystem, alongside responsible use and global access.

Limits of Pipeline Evidence

A study evaluating the US public–private Combating Antibiotic-Resistant Bacteria Accelerator (CARB-X) focuses on intermediate drug-development outcomes because there has been limited time to assess application outcomes. The authors say a more robust analysis—including approvals—should be conducted later, when more applications and a longer development history are available. Separately, WHO’s June 2024 clinical-development dataset is limited to human-use products in phases I–III without market authorization anywhere in the world, with a data cut-off of December 31, 2023.

Resistance Mechanisms and Drug Design

Understanding the types and mechanisms of antibacterial resistance can help researchers develop more effective treatment strategies, according to a 2024 Frontiers review. The review describes how studying bacterial evasion of antibacterials can guide the design of drugs that target resistance mechanisms. A 2025 review likewise identifies antibiotic overuse and misuse in medical and agricultural settings as major drivers of resistance, which complicates management of bacterial infections.

Funding the clinical trials for new antibiotics is another major hurdle. Phase I to III trials can cost upwards of $130 million, with post-approval follow-on trials adding another $146 million. Small- and medium-sized enterprises (SMEs), which now dominate the antibiotic development space, often struggle to raise the necessary capital.

Charting a Path Forward for Antibiotic R&D

The challenges in antibiotic R&D are significant, but not insurmountable. By addressing the economic barriers, fostering scientific innovation, and implementing effective incentives, we can pave the way for a new generation of antibiotics that will protect public health for years to come. It's time for global collaboration and decisive action to ensure a future where antibiotic resistance is no longer a threat.

AI Search Multiple angles on this topic

Future Strategies Against Resistance

A 2025 DrugBank article describes the rollout of antibiotics in the 20th century as having significantly reduced mortality, while noting that bacteria have increasingly developed resistance to these drugs. It frames pharmaceutical-industry responses as an emerging area of antibiotic development. A review of current trends and future strategies highlights rising resistance among bacterial sepsis, global antibiotic-consumption patterns, and increasing mortality linked to drug-resistant infections.

Innovation and Systemic Pressures

A 2025 article says antibiotic resistance develops as bacteria adapt to evade antibiotics, often under misuse, overuse, and selective pressure. It identifies limited drug-development innovation, profit-driven healthcare practices, and the absence of diagnostic testing before treatment as factors that have exacerbated resistance. The source presents these as interconnected pressures on efforts to address antibiotic resistance.

Resistance Across Cases and Countries

A 2024 Frontiers review examines trends in antibiotic resistance and the growing risk posed by superbugs, drawing on fundamental resistance mechanisms and individual case reports. A separate review analyzes molecular and ecological mechanisms and evaluates global containment efforts to identify strategies for mitigating antimicrobial resistance. A 2025 ResearchGate listing reports that lysogenic bacteriophages can act as vectors for acquiring and disseminating antibiotic-resistance genes.

What the antibiotic pipeline figures mean

  • 12% and 7%Large biopharmaceutical companies discovered 12% of the antibacterial therapeutics being tested in the clinic, compared with 7% discovered by small non-profit organizations.[1]
  • 16.3% success rateThe reported Phase I-to-FDA-approval success rate for antibacterial new chemical entities was 16.3% during 2011–2020.[1]
  • 244 candidates; 141 groupsThe preclinical analysis identified 244 potential candidates from 141 developer research groups.[2]

What the antibiotic development figures show

The discovery shares show that large biopharmaceutical firms and small non-profits account for different portions of the clinical-stage therapeutics; they do not describe the contributions of every developer type.[1]

The candidate and group counts indicate activity before clinical testing, but the analysis may not capture the full preclinical work of large pharmaceutical companies, which can remain undisclosed until later.[2]

How funding and pipeline analyses compare

A systematic review of recommendations for revitalizing the antibiotic pipeline found that most of the included articles advocated mixed or hybrid financial incentives. Separately, a review describes push and pull incentives as responses to weak commercial returns for newly launched antimicrobial agents.[3] [4]

A review of indirect funding cautions that equal payments for all drugs could reward products with little innovation, even if early-phase prizes may be cost-effective compared with direct funding. This highlights a design tension between supporting development and distinguishing its degree of innovation.[5]

What remains unresolved in antibiotic R&D

  • How well do reported clinical-stage counts represent the pipeline when some products and trial results are not publicly registered or reported?[6]
  • Can incentive models support development while accounting for differences in societal value and innovativeness?[3] [5]
  • How much preclinical activity remains uncounted when large companies disclose projects only as they approach clinical development?[2]

Sources

  1. www.bio.org (www.bio.org)
  2. Multi-year analysis of the global preclinical antibacterial pipeline: trends and gaps (pmc.ncbi.nlm.nih.gov)
  3. Encouraging the Development of New Antibiotics: Are Financial Incentives the Right Way Forward? A Systematic Review and Case Study - PMC Lock (pmc.ncbi.nlm.nih.gov)
  4. A Broken Antibiotic Market: Review of Strategies to Incentivize Drug Development (pmc.ncbi.nlm.nih.gov)
  5. Economics of Public Antibiotics Development (www.frontiersin.org)
  6. Antibacterial products in clinical development for priority pathogens (Jun 2024) (www.who.int)

About this Article -

Written with AI assistance from published research, and reviewed by the Mystum team. See our About page for more information.

Everything You Need To Know

1

What are the main reasons behind the current crisis in antibiotic research and development (R&D)?

The antibiotic R&D crisis stems from a combination of economic, regulatory, and scientific challenges. Economically, developers face distress throughout the value chain. Scientifically, identifying new antibacterial molecules and mechanisms of action has become increasingly difficult. This is further compounded by regulatory complexities, creating an environment that discourages investment and innovation in the field.

2

Why is the decrease in the number of experts in antibiotic discovery a significant concern?

The decline in experts in antibiotic discovery is significant because the closure of research centers and the divestiture by pharmaceutical companies have led to a shrinking talent pool. Without these experts, the ability to identify and develop new antibacterial molecules and mechanisms of action is severely hampered, stalling progress in combating antibiotic resistance.

3

Why is funding clinical trials for new antibiotics such a major challenge?

Funding the clinical trials for new antibiotics is a major hurdle due to the high costs involved. Phase I to III trials can cost upwards of $130 million, with post-approval follow-on trials adding another $146 million. This financial burden particularly affects small- and medium-sized enterprises (SMEs), which now dominate the antibiotic development space but often struggle to raise the necessary capital.

4

Why are the scientific difficulties in identifying new antibacterial molecules and mechanisms of action so important?

The scientific difficulties in identifying new antibacterial molecules and mechanisms of action are critical because traditional methods of studying natural antimicrobial activities have become less effective. This challenge slows down the initial discovery phase, making it harder to find promising new drug candidates.

5

Why is it so important to address the economic barriers that hinder antibiotic R&D?

Addressing the economic barriers in antibiotic R&D is essential because these barriers create significant distress for developers throughout the entire value chain. By alleviating these economic pressures, fostering scientific innovation, and implementing effective incentives, it can pave the way for a new generation of antibiotics to protect public health. Without addressing these issues, antibiotic resistance will continue to pose a major threat.

Newsletter Subscribe

Subscribe to get the latest articles and insights directly in your inbox.